ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”),
an advanced materials company dedicated to the development of
technology and processes for the production of isotopes for use in
multiple industries, today announced that it has received a
purchase order from a leading global industrial gases company to
supply highly enriched silicon-28. The product is expected to be
supplied from the Company’s South African production facility and
shipped to the customer in the USA during 2024.
ASP Isotopes expects highly enriched silicon-28
to be required by manufacturers of next-generation semiconductors.
Naturally occurring silicon has three isotopes – 28, 29 and 30. The
29 isotope has a ½ positive spin, which is an intrinsic form of
angular momentum carried by elementary particles. In contrast,
highly enriched silicon-28 is spin-free where qubits are protected
from sources of decoherence that causes loss of quantum
information(1). In addition to its potential to process superior
information such as qubits, it is believed that highly enriched
silicon-28 can conduct heat 150% more efficiently(2) than natural
silicon, which will potentially allow for chips to become smaller,
faster and cooler.
ASP Isotopes’ proprietary technology can enrich
isotopes of low atomic mass (such as silane (SiH4), molecular mass
of 32), as well as isotopes of heavier masses. Other companies
developing methods to enrich silicon generally either enrich
silicon tetrafluoride (SiF4) or a halo silane. Neither of these
chemicals can be used directly by a semiconductor company and
require chemical converting processes that potentially harm the
purity of the final product. By processing silane directly, the
Company believes that its finished product will be a higher quality
and may be used by semiconductor companies without the need for
additional chemical conversion processes.
“To create faster, smaller next-generation
semiconductors, the world is likely going to require materials that
are currently not available in commercial quantities”, said Paul
Mann, ASP Isotopes’ Chairman and Chief Executive Officer. “ASP
Isotopes is currently working on many isotopically pure elements
that we believe will help semiconductor companies create the chips
that the world will require in the future to enable technologies
such as quantum computing and artificial intelligence.”
ASPI’s South African multi-isotope production
facility is expected to be capable of producing up to 10 Kgs of
highly enriched silicon-28 per annum. To meet the anticipated
demand later this decade, the Company anticipates constructing a
larger silicon-28 production facility as part of the proposed
Icelandic cluster, slated to start production during 2026. The
Company expects to start the construction of its Icelandic
facilities during 2024 with first production of medical isotopes
expected in 2025. The Company is in discussions with many
companies, both in the semiconductor industry as well as healthcare
industries regarding their requirements for products that might be
produced from the Icelandic cluster.
(1)
Isotopically Enriched Layers for Quantum Computers Formed by
28Si Implantation and Layer Exchange, Schneider, E and England, J;
ACS Appl. Mater. Interfaces 2023, 15, 17, 21609–21617
(2) Penghong Ci, Muhua Sun, Meenakshi Upadhyaya,
Houfu Song, Lei Jin, Bo Sun, Matthew R. Jones, Joel W. Ager, Zlatan
Aksamija, and Junqiao Wu Phys. Rev. Lett. 128, 085901 – Published
23 February 2022
About ASP Isotopes Inc.
ASP Isotopes Inc. is a pre-commercial stage
advanced materials company dedicated to the development of
technology and processes to produce isotopes for use in multiple
industries. The Company employs proprietary technology, the
Aerodynamic Separation Process (“ASP technology”). The Company’s
initial focus is on producing and commercializing highly enriched
isotopes for the healthcare and technology industries. The Company
also plans to enrich isotopes for the nuclear energy sector using
Quantum Enrichment technology that the Company is developing. The
Company has isotope enrichment facilities in Pretoria, South
Africa, dedicated to the enrichment of isotopes of elements with a
low atomic mass (light isotopes).
There is a growing demand for isotopes such as
Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and
Nickel-64 for new, emerging healthcare applications, as well as
Chlorine-37, Lithium-6, and Uranium-235 for green energy
applications. The ASP Technology (Aerodynamic Separation Process)
is ideal for enriching low and heavy atomic mass molecules. For
more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including,
without limitation, statements about the importance and
implications of the purchase orders from its customers, statements
relating to the development of new technology for the enrichment of
nuclear isotopes, the commencement of supply of isotopes to
customers, and the construction of additional enrichment
facilities. Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy, and other future
conditions. Forward-looking statements can be identified by words
such as “believes,” “plans,” “anticipates,” “expects,” “estimates,”
“projects,” “will,” “may,” “might,” and words of a similar nature.
Examples of forward-looking statements include, among others but
are not limited to, statements we make regarding expected operating
results, such as future revenues and prospects from the potential
commercialization of isotopes, future performance under contracts,
and our strategies for product development, engaging with potential
customers, market position, and financial results. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks, and changes in circumstances that
are difficult to predict, many of which are outside our control.
Our actual results, financial condition, and events may differ
materially from those indicated in the forward-looking statements
based upon a number of factors. Forward-looking statements are not
a guarantee of future performance or developments. You are strongly
cautioned that reliance on any forward-looking statements involves
known and unknown risks and uncertainties. Therefore, you should
not rely on any of these forward-looking statements. There are many
important factors that could cause our actual results and financial
condition to differ materially from those indicated in the
forward-looking statements, including our reliance on the efforts
of third parties; our ability to complete the construction and
commissioning of our enrichment plants or to commercialize isotopes
using the ASP technology or the Quantum Enrichment Process; our
ability to obtain regulatory approvals for the production and
distribution of isotopes; the financial terms of any current and
future commercial arrangements; our ability to complete certain
transactions and realize anticipated benefits from acquisitions;
contracts, dependence on our Intellectual Property (IP) rights,
certain IP rights of third parties; and the competitive nature of
our industry. Any forward-looking statement made by us in this
press release is based only on information currently available to
us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise. This press release includes market and industry data and
forecasts that we obtained from internal research, publicly
available information and industry publications and surveys.
Industry publications and surveys generally state that the
information contained therein has been obtained from sources
believed to be reliable. Unless otherwise noted, statements as to
our potential market position relative to other companies are
approximated and based on third-party data and internal analysis
and estimates as of the date of this press release. We have not
independently verified this information, and it could prove
inaccurate. Industry and market data could be wrong because of the
method by which sources obtained their data and because information
cannot always be verified with certainty due to the limits on the
availability and reliability of raw data, the voluntary nature of
the data-gathering process and other limitations and uncertainties.
In addition, we do not know all of the assumptions regarding
general economic conditions or growth that were used in preparing
the information and forecasts from sources cited herein. No
information in this press release should be interpreted as an
indication of future success, revenues, results of operation, or
stock price. All forward-looking statements herein are qualified by
reference to the cautionary statements set forth herein and should
not be relied upon.
Contacts
Jason Assad– Investor
relationsEmail: Jassad@aspisotopes.comTelephone:
561-709-3043
ASP Isotopes (NASDAQ:ASPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ASP Isotopes (NASDAQ:ASPI)
Historical Stock Chart
From Sep 2023 to Sep 2024